Ipamorelin: Discovery and Regulatory History

Introduction

Ipamorelin's history spans the late 1990s growth hormone secretagogue research programs at Novo Nordisk A/S, the subsequent identification of ghrelin as the endogenous ligand for the receptor ipamorelin targets, and a clinical development program that progressed through human phase 2 investigation. Understanding this history requires situating ipamorelin within the broader arc of GHS pharmacology — a field that began with observations about synthetic opioid peptides in the 1970s and evolved over two decades into a defined receptor pharmacology supporting multiple pharmaceutical programs and, ultimately, the first FDA-approved compound in the ghrelin receptor agonist class.

Discovery Period: The GHRP Research Tradition

The scientific preconditions for ipamorelin's development were established over approximately two decades of growth hormone secretagogue research. In the mid-1970s, Cyril Bowers and colleagues at Tulane University observed that certain synthetic enkephalin analogs — modifications of opioid peptides — possessed an unexpected capacity to stimulate GH release from pituitary tissue in vitro and in vivo. This observation was not explained by opioid receptor pharmacology alone, suggesting the existence of a distinct receptor system for these GH-releasing peptides.

Bowers and colleagues subsequently characterized the first generation of dedicated growth hormone-releasing peptides (GHRPs), including GHRP-6, through structure-activity relationship studies during the 1980s. These hexapeptides demonstrated significant GH-releasing potency but also stimulated ACTH, cortisol, and prolactin — a feature that complicated pharmacological profiling and motivated continued structural optimization within the class.

Parallel development at Merck Research Laboratories, led by Roy Smith and colleagues, produced the first non-peptidyl growth hormone secretagogues, including MK-0677 (ibutamoren), through an iterative medicinal chemistry effort. The molecular cloning of GHS-R1a was reported by Howard and colleagues from Merck in 1996, providing the pharmacological framework within which ipamorelin's discovery would be interpreted and the receptor class formally named.

Early Research: Ipamorelin's Characterization at Novo Nordisk

Ipamorelin emerged from a GHS research program at Novo Nordisk A/S in Måløv, Denmark, in the late 1990s. The lead investigators — K. Raun, B.S. Hansen, N.L. Johansen, H. Thøgersen, K. Madsen, M. Ankersen, and P.H. Andersen — identified the pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) within a series of compounds derived from modifications to the GHRP-1 scaffold, specifically from structures lacking the central dipeptide Ala-Trp that had been a recurring motif in earlier GHRPs.

The foundational characterization was published in the European Journal of Endocrinology in November 1998 [1]. This paper established several properties of ipamorelin that would define its scientific identity: high GH-releasing potency in primary rat pituitary cells and in conscious swine in vivo; a selectivity profile in which ACTH, cortisol, FSH, LH, prolactin, and TSH were not significantly elevated even at doses more than 200-fold above the ED₅₀ for GH release; and pharmacological evidence that ipamorelin acted through a GHRP-like receptor rather than the GHRH receptor. The compound's development code was NNC 26-0161.

Also in 1998, Ankersen and colleagues published a companion report in the Journal of Medicinal Chemistry describing the SAR program that ipamorelin anchored, in which the pentapeptide served as a structural template for a new generation of GHS compounds [2]. Johansen and colleagues published pharmacokinetic characterization the same year, reporting comparative plasma clearance and excretion profiles for ipamorelin alongside GHRP-2 and GHRP-6, with findings indicating a lower clearance rate and predominantly urinary excretion for ipamorelin [3].

The Ghrelin Discovery and Its Impact on Ipamorelin's Scientific Context

A pivotal recontextualization of ipamorelin's pharmacology occurred in 1999, when Kojima and colleagues at Kurume University in Japan identified ghrelin — a 28-amino acid acylated peptide predominantly produced by gastric X/A-like cells — as the endogenous ligand for GHS-R1a. Published in Nature in December 1999, the ghrelin discovery transformed the scientific framing of GHS-R1a agonists from "GHRP-like agonists" to "ghrelin mimetics" or "ghrelin receptor agonists," providing an endogenous physiological anchor for the receptor target.

For ipamorelin, this shift was conceptually significant: the compound, initially characterized strictly in the context of GH release and GHRP pharmacology, was now understood to act on a receptor that also mediated appetite regulation, gastric motility, and energy homeostasis in normal physiology. This broader receptor biology opened new research directions for ipamorelin beyond the pituitary somatotroph axis and informed the gastrointestinal research program that followed.

Preclinical Research Expansion (1999–2004)

Following the 1998 characterization papers, a series of preclinical studies extended the ipamorelin research profile into new domains.

Johansen and colleagues (1999) reported that ipamorelin administration was associated with dose-dependent longitudinal bone growth in rats over a 15-day study, attributing this effect to GH-mediated downstream actions [4]. The study contributed to the understanding of ipamorelin's systemic effects beyond the acute pituitary level.

Malmlöf and colleagues (1999) examined ipamorelin's interaction with the glucocorticoid methylprednisolone in rats, reporting that the glucocorticoid did not abrogate GH responsiveness to ipamorelin and that repeated ipamorelin administration was associated with preserved body weight-related endpoints in glucocorticoid-treated animals [5].

Jiménez-Reina and colleagues (2002) published a histological and functional investigation of somatotroph cell responses to chronic ipamorelin administration in young female rats, describing morphological changes and altered in vitro GH responsiveness in pituitary tissue from chronically treated animals — findings that contributed to the characterization of pituitary adaptation under sustained GHS-R1a stimulation [6].

Adeghate and Ponery (2004) reported that ipamorelin was associated with insulin secretion from isolated pancreatic fragments in both normal and streptozotocin-diabetic rats in vitro, with pharmacological evidence implicating calcium and adrenergic receptor pathways — the first published characterization of ipamorelin's effects in pancreatic tissue [7].

Clinical Development and Regulatory Milestones

Postoperative Ileus Program

Ipamorelin's clinical development program concentrated on postoperative ileus (POI) — a condition characterized by delayed return of gastrointestinal motility following abdominal surgery — a therapeutic direction informed by the growing body of preclinical evidence concerning ghrelin receptor agonists and gastrointestinal physiology.

Venkova and colleagues (2009) contributed preclinical support for this direction, reporting that ipamorelin was associated with changes in colonic transit in a rodent model of POI [8]. Greenwood-Van Meerveld and colleagues (2012) added mechanistic data from gastric preparations, reporting that ipamorelin restored suppressed contractile responses in surgically manipulated gastric tissue through what the authors attributed to GHS-R1a–mediated cholinergic activation — findings that informed the mechanistic rationale for clinical investigation [9].

Clinical trials for the POI indication were registered with ClinicalTrials.gov under identifiers NCT00672074 and NCT01280344, with Helsinn Therapeutics (U.S.), Inc. listed as the sponsoring organization. These phase 2 studies enrolled patients undergoing bowel resection with primary anastomosis and evaluated ipamorelin on gastrointestinal recovery endpoints.

Beck and colleagues published results from the multicenter, double-blind, proof-of-concept phase 2 trial (the Ipamorelin 201 study) in the International Journal of Colorectal Disease in 2014 [10]. The trial enrolled 117 patients and reported that ipamorelin was well tolerated, with adverse event rates similar between treatment and placebo groups. The median time to tolerating a solid meal was 25.3 hours (ipamorelin) versus 32.6 hours (placebo) — a directional difference that did not achieve statistical significance (p=0.15) on the primary composite gastrointestinal endpoint in this proof-of-concept cohort. The trial contributed human safety and tolerability data and informed the broader scientific understanding of ghrelin receptor agonism in a clinical postoperative setting, while also establishing that the primary endpoint as defined was not met at the studied dose in that patient population.

FDA Compounding Advisory Review

Ipamorelin came under FDA regulatory review in the context of pharmaceutical compounding. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies may compound drug products from bulk drug substances only if the substances meet specified criteria. Ipamorelin does not have an approved USP or NF monograph and is not an active ingredient in any FDA-approved drug product.

The FDA's Pharmacy Compounding Advisory Committee (PCAC) considered ipamorelin at its October 2024 meeting as part of ongoing evaluation of bulk drug substances nominated for inclusion on or exclusion from the 503A bulks list. These proceedings are part of the FDA's systematic review of the regulatory status of peptide compounds used in compounding and represent the compound's most recent regulatory milestone in the United States.

Current Research Landscape

The ghrelin receptor agonist field has continued to progress with other compounds in the years following the Helsinn-sponsored POI program. Relamorelin (RM-131), a modified ghrelin peptide, was evaluated in phase 2 clinical trials for diabetic gastroparesis with publications appearing between 2015 and 2019. Macimorelin, a non-peptidyl GHS-R1a agonist, received FDA marketing approval in December 2017 under the brand name Macrilen for diagnosis of adult growth hormone deficiency — the first FDA-approved compound in the ghrelin receptor agonist class, a milestone that validated GHS-R1a as a pharmacologically actionable target for human diagnostic applications. Research in the broader GH secretagogue class has also advanced with GHRH analog programs; the development history of tesamorelin offers a comparative arc within the same cluster.

Ipamorelin's scientific contribution to this landscape is recognized in the literature primarily for establishing, through its selectivity data, that GHS-R1a agonism could be pharmacologically dissociated from co-stimulation of the HPA axis — a finding that demonstrated signal diversity at the GHS-R1a receptor and informed compound design efforts within the class. The compound remains available as a research-use-only material in preclinical research settings and continues to be cited in the primary literature as a pharmacological reference point for selective GHS-R1a agonism. Verified research-grade ipamorelin from SpartaLabs is available with batch-level certificate of analysis documentation.

References

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822. DOI: 10.1530/eje.0.1390552

2. Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J Med Chem. 1998;41(19):3699-704. PMID: 9733495. DOI: 10.1021/jm9801962

3. Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083-92. PMID: 9879640. DOI: 10.1080/004982598238976

4. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. PMID: 10373343. DOI: 10.1054/ghir.1999.9998

5. Malmlöf K, Johansen PB, Haahr PM, Wilken M, Oxlund H. Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth Horm IGF Res. 1999;9(6):445-50. PMID: 10629165. DOI: 10.1054/ghir.1999.0128

6. Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Influence of chronic treatment with the growth hormone secretagogue ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002;17(3):707-14. PMID: 12168778. DOI: 10.14670/HH-17.707

7. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinol Lett. 2004;25(6):403-6. PMID: 15665799.

8. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-6. PMID: 19289567.

9. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-55. PMID: 27186127. DOI: 10.2147/JEP.S35396

10. Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PMID: 25331030. DOI: 10.1007/s00384-014-2030-8